Orchestra BioMed Holdings, Inc.
Orchestra BioMed (OBIO) completed its BACKBEAT trial with 330 patients, exceeding the 316-patient target. The global trial, conducted at 81 sites across 13 countries, aims to support Medtronic's regulatory applications. Primary endpoint data is expected to be submitted for presentation in Q2 2027, according to the company.
Orchestra BioMed Holdings, Inc. (OBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy · 330 patients randomized as of September 30, 2026, surpassing full trial enrollment target · Company reiterates prior guidance: primary endpoint data to be submitted
Orchestra BioMed (OBIO) received a $6.1M milestone payment from Haemonetics (HAE) following HAE's acquisition of Vivasure. This adds to a prior $5M upfront payment, with potential for $10M more in earnouts. The funds will support OBIO's AVIM and Virtue SAB clinical trials. HAE's stock closed at $106.31, up 3.53%.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning OBIO (Orchestra BioMed Holdings, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent OBIO coverage spans market movers, financial news and corporate actions.
In the last 30 days, OBIO insiders filed 2 SEC Form 4 transactions — 1 purchase ($48K) and 1 sale ($74K). The most active reporter was Hochman David P, See Remarks, with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Enrollment beat suggests trial progress and may boost investor confidence ahead of data readout.
The enrollment milestone removes a key execution risk and positions the company for data readout in Q2 2027, which could drive the stock higher if results are positive.
Cash infusion improves balance sheet and funds ongoing clinical trials.
Executive visibility supports market enthusiasm for its hypertension and atherosclerosis programs.
Analyst upgrade may sustain price rally.
AlphAI scores every news story that mentions OBIO with an AI model for sentiment and relevance, and aggregates insider trades from Orchestra BioMed Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Orchestra BioMed (OBIO) completed its BACKBEAT trial with 330 patients, exceeding the 316-patient target. The global trial, conducted at 81 sites across 13 countries, aims to support Medtronic's regulatory applications. Primary endpoint data is expected to be submitted for presentation in Q2 2027, according to the company.
1 min readOrchestra BioMed Holdings, Inc. (OBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy · 330 patients randomized as of September 30, 2026, surpassing full trial enrollment target · Company reiterates prior guidance: primary endpoint data to be submitted
2 min readOrchestra BioMed (OBIO) received a $6.1M milestone payment from Haemonetics (HAE) following HAE's acquisition of Vivasure. This adds to a prior $5M upfront payment, with potential for $10M more in earnouts. The funds will support OBIO's AVIM and Virtue SAB clinical trials. HAE's stock closed at $106.31, up 3.53%.
1 min readTenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.
3 min readWealthfront (WLTH) shares rose 6.6% to $10.08 after reporting Q2 earnings of $0.10 per share, beating estimates. Other stocks gaining include Orchestra BioMed (OBIO) +8.4%, AeroVironment (AVAV) +7.2%, and Molina Healthcare (MOH) +6.1%.
2 min readHochman David P (See Remarks) purchased 10,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.79 on 2026-09-03.
1 min readSeveral biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.
3 min readAmylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.
4 min readOrchestra BioMed Holdings, Inc. (OBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001814114 0001814114 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
3 min readHochman David P (See Remarks) purchased 5,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $3.83 on 2026-06-01.
2 min read
